self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnostics
PRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries.
Projectdetails
Introduction
Despite huge progress in prevention and treatment over the past century, infectious diseases still impose a great health burden. For this reason, lab-centralised immunoassays and nucleic acid tests that allow for specific pathogen identification with limits of detection reaching few copies per ml of sample are readily available and supported by both national and private health systems in the developed world.
Accessibility Issues
However, these tests are neither affordable nor accessible to patients in low- and medium-income countries. Fortunately, lateral flow antigen-based tests have proven to be a fast, reliable, and affordable tool to detect a wide range of pathogens.
Limitations of Current Tests
However, such tests suffer from cross-reactivity with related bacterial or viral species and, more importantly, they often require 10^5 pathogens per mL to yield a positive result.
Clinical and Technological Need
It becomes clear that there is a clinical and technological need to develop rapid tests that combine PCR sensitivity able to detect one copy per mL with lateral flow affordability.
Proposed Solution
PRONTO proposes a novel low-cost, sustainable, and self-powered readout system for nucleic acid detection based on conductimetry. The key component consists of a paper-based and single-use self-powered conductimetric sensor developed during ERC Consolidator Grant SUPERCELL.
Unique Sensing Approach
The sensing approach is unique and minimalistic, as it breaks the classic paradigm of sensor-electronics-battery. The sensor and the power source are merged into one element while making the detection system energetically autonomous.
Global Impact
The simplicity of the approach will enable the deployment of highly sensitive and digital tests for infectious diseases at affordable prices and in a sustainable manner at a global scale.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-6-2023 |
Einddatum | 30-11-2024 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Novel ApameR-Based Rapid Test Technology for Virus DetectionDeveloping a cost-effective RNA aptamer-based sensor for rapid point-of-care testing of avian influenza, meeting WHO ASSURED criteria, to enhance pathogen detection and containment. | ERC Proof of... | € 150.000 | 2023 | Details |
Rapid chip-based detection of antibiotic resistancesDeveloping ResisCHIP, a rapid RNA diagnostic tool for bacterial infections, to enhance treatment selection and combat antimicrobial resistance within 2 hours from blood samples. | ERC Proof of... | € 150.000 | 2022 | Details |
Fast and simple biomarker detection by computational microscopyWe developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics. | ERC Proof of... | € 150.000 | 2024 | Details |
CRISPR Point-of-Care DiagnosticsDeveloping a streamlined, one-step CRISPR-Cas diagnostic tool for rapid and accurate detection of COPD pathogens, enhancing point-of-care diagnostics and commercialization potential. | ERC Proof of... | € 150.000 | 2022 | Details |
Affordable and sustainable self-powered GLUCOSE sensing system for a global FAIR diabetes managementFAIRGLUCOSE aims to develop a low-cost, self-powered glucose sensing system that reduces waste and enhances accessibility for glucose monitoring, especially in low-income regions. | ERC Proof of... | € 150.000 | 2022 | Details |
Novel ApameR-Based Rapid Test Technology for Virus Detection
Developing a cost-effective RNA aptamer-based sensor for rapid point-of-care testing of avian influenza, meeting WHO ASSURED criteria, to enhance pathogen detection and containment.
Rapid chip-based detection of antibiotic resistances
Developing ResisCHIP, a rapid RNA diagnostic tool for bacterial infections, to enhance treatment selection and combat antimicrobial resistance within 2 hours from blood samples.
Fast and simple biomarker detection by computational microscopy
We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.
CRISPR Point-of-Care Diagnostics
Developing a streamlined, one-step CRISPR-Cas diagnostic tool for rapid and accurate detection of COPD pathogens, enhancing point-of-care diagnostics and commercialization potential.
Affordable and sustainable self-powered GLUCOSE sensing system for a global FAIR diabetes management
FAIRGLUCOSE aims to develop a low-cost, self-powered glucose sensing system that reduces waste and enhances accessibility for glucose monitoring, especially in low-income regions.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
ECL-based Infectious Pathogen (bio)SEnsorECLIPSE aims to develop a portable, cost-effective platform using ultrasensitive detection methods for rapid identification of infectious pathogens, enhancing response to future pandemics. | EIC Pathfinder | € 2.683.996 | 2022 | Details |
Leveraging CRISPR-Cas for fast and accurate point-of-care diagnosticsScope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare. | EIC Transition | € 2.498.125 | 2024 | Details |
Microfluïde assay on-a-chip voor detectie bacteriële infectiesLevels Diagnostics en Digi.Bio ontwikkelen een innovatieve lab-on-a-chip test voor snelle en betrouwbare differentiatie tussen virale en bacteriële luchtweginfecties om onnodig antibioticagebruik te verminderen. | Mkb-innovati... | € 180.528 | 2018 | Details |
GAAFSTE: GrAfeen nAnosensoren voor Fast (snelle) antibiotica Susceptibiliteit TEstDit project ontwikkelt een snel prototype voor antibiotica susceptibiliteitstests, dat binnen 2 uur resultaten levert, om de effectiviteit van antibiotica te optimaliseren en resistentie tegen te gaan. | Mkb-innovati... | € 275.555 | 2022 | Details |
Sneltest bacteriele ziekteverwekkersHet project onderzoekt de haalbaarheid van een betaalbare SERS-sneltest voor bacteriële ziekteverwekkers om de toegang tot zorg te verbeteren en diagnostiek te democratiseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
ECL-based Infectious Pathogen (bio)SEnsor
ECLIPSE aims to develop a portable, cost-effective platform using ultrasensitive detection methods for rapid identification of infectious pathogens, enhancing response to future pandemics.
Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics
Scope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare.
Microfluïde assay on-a-chip voor detectie bacteriële infecties
Levels Diagnostics en Digi.Bio ontwikkelen een innovatieve lab-on-a-chip test voor snelle en betrouwbare differentiatie tussen virale en bacteriële luchtweginfecties om onnodig antibioticagebruik te verminderen.
GAAFSTE: GrAfeen nAnosensoren voor Fast (snelle) antibiotica Susceptibiliteit TEst
Dit project ontwikkelt een snel prototype voor antibiotica susceptibiliteitstests, dat binnen 2 uur resultaten levert, om de effectiviteit van antibiotica te optimaliseren en resistentie tegen te gaan.
Sneltest bacteriele ziekteverwekkers
Het project onderzoekt de haalbaarheid van een betaalbare SERS-sneltest voor bacteriële ziekteverwekkers om de toegang tot zorg te verbeteren en diagnostiek te democratiseren.